Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors

Area of Science:

• Immunology
• Oncology
• Bone Biology

Background:

• Colony stimulation factor-1 receptor (CSF-1R), also known as FMS kinase, regulates innate immunity, macrophage differentiation, and survival.
• Overstimulation of CSF-1R by its ligand CSF-1 is implicated in inflammatory, cancer, and bone disorders.
• Interleukin-34 (IL-34) is a newly identified ligand that activates CSF-1R through a distinct mechanism.

Purpose of the Study:

• To discuss the roles of CSF-1 and IL-34 in cancer, bone disorders, and inflammation.
• To review novel small molecule kinase inhibitors and monoclonal antibodies targeting CSF-1R.
• To highlight advancements in CSF-1R-targeted therapies from 2012 to 2017.

Main Methods:

• Literature review of studies on CSF-1R, CSF-1, and IL-34.
• Analysis of research on CSF-1R inhibitors and antibodies in preclinical and clinical settings.
• Focus on therapeutic strategies targeting CSF-1R signaling pathways.

Main Results:

• CSF-1R signaling is crucial in the pathogenesis of various diseases.
• Both CSF-1 antibodies and small molecule CSF-1R kinase inhibitors have demonstrated efficacy in animal models and human trials.
• Recent developments include potent small molecule inhibitors and monoclonal antibodies with significant activity against CSF-1R.

Conclusions:

• CSF-1R, CSF-1, and IL-34 are critical players in cancer, inflammation, and bone diseases.
• Targeting CSF-1R with novel inhibitors and antibodies represents a promising therapeutic approach.
• Continued research and development in CSF-1R-targeted therapies are essential for treating related disorders.